Overview

Study to Evaluate the Efficacy and Safety of DWP14012 on Maintaining Healing in Subjects With Healed Erosive Esophagitis

Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
This study aims to demonstrate the noninferiority of DWP14012 to Lansoprazole 15 mg in the maintenance effect of treatment and confirm the safety of DWP14012 in patients with healed erosive esophagitis confirmed on EGD after medication treatment.
Phase:
Phase 3
Details
Lead Sponsor:
Daewoong Pharmaceutical Co. LTD.
Treatments:
Dexlansoprazole
Lansoprazole